Generated August 19, 2026 at 8:33 PM ET
· Covers August 19 trading day
· 10 of 166 ready 8-Ks selected
· AI-assisted overview
Several high-materiality filings were made on August 19, 2026. Internet Sciences ( ) disclosed the resignation of seven directors over four days, with no cited disagreements. In M&A activity, Crinetics Pharmaceuticals (CRNX) faced shareholder lawsuits over its Vertex merger and supplemented proxy disclosures, while ZeroStack Corp. (ZSTK) announced a $1B token acquisition, Datavault AI (DVLT) closed its NYIAX purchase, and HIVE Digital (HIVE) signed a $350M GPU cloud deal. Regulatory news included Ultragenyx (RARE) receiving FDA accelerated approval for GENGLYCOS, Aurinia (AUPH) settling patent litigation to delay generic entry, and Mereo BioPharma (MREO) receiving a second Nasdaq bid-price notice. Delisting risks emerged for OSR Holdings (OSRH) with suspension and appeal planned, while Arrive AI (ARAI) cut jobs and adjusted debt terms. The day's filings were dominated by operational and transactional updates, with several companies addressing listing standards or clinical/regulatory milestones.
—
INTERNET SCIENCES INC.
leadership
negative
materiality 0.85
August 19, 2026, 5:15 PM ET
Seven directors resign from Internet Sciences board over four days
- Michael Kahn resigned Aug 14, 2026, effective immediately; no disagreement cited.
- Dimitrius M. Hutcherson and Keith R. Wyche resigned Aug 15, 2026, effective immediately.
- Dr. Mark T. Maybury, James C. Forbes, Mark Deutsch, Debra Bigman resigned Aug 16-17, 2026.
CRNX
Crinetics Pharmaceuticals, Inc.
M&A
negative
materiality 0.80
August 19, 2026, 4:04 PM ET
Crinetics supplements proxy disclosures amid shareholder lawsuits over Vertex merger
- Three shareholder lawsuits filed Aug 6 & 17, 2026 in NY and CA allege misleading proxy disclosures; seek to block merger.
- Board unanimously reaffirms 'FOR' recommendation on merger and related proposals; special shareholder meeting set for Aug 28, 2026.
- Supplemental disclosures add J.P. Morgan and Leerink valuation analyses; updated projections show revenue rising to $1,057M by 2030E and $4,583M by 2035E.
M&A
positive
materiality 0.90
August 19, 2026, 9:26 AM ET
ZeroStack acquires $1B in MemeCore tokens; issues shares/warrants at $25.19, 12x premium
- Issued 3.5M shares and pre-funded warrants for 36.2M shares at $25.19/share to Puple AI and Blockcat for 925.9M MemeCore tokens valued at $1.08 each (~$1B).
- Share price represents >12x premium to recent market price; warrants subject to 10-year lock-up and shareholder approval for shares beyond 19.99% cap.
- Rudy Rong appointed President; employment agreement includes $500k base salary, 125k restricted stock grant (subject to shareholder approval), and 24-month severance (30 months on change in control).
M&A
positive
materiality 0.85
August 19, 2026, 5:30 PM ET
Datavault AI closes NYIAX acquisition, issues 74.8M shares for exchange tech
- Closed acquisition of NYIAX on Aug 18, 2026; issued 74,800,629 shares of common stock as Merger Consideration.
- Paid ~$494,859 in cash to unaccredited investors; Exchange Ratio ~1.41 Datavault shares per NYIAX share.
- NYIAX brings institutional-grade exchange tech, blockchain settlement, and four issued U.S. patents (Nos. 10,607,291; 11,410,236; 11,861,707; 12,198,193).
RARE
Ultragenyx Pharmaceutical Inc.
regulatory
positive
materiality 0.85
August 19, 2026, 5:24 PM ET
Ultragenyx wins FDA accelerated approval for GENGLYCOS (DTX401) in GSDIa
- FDA granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr) in GSDIa patients aged 8+.
- Approval based on Phase 3 GlucoGene: 46 participants, cornstarch requirement reduction at Week 48 (p<0.001).
- Efficacy data from 44 mITT (DTX401 n=20, placebo n=24); crossover followed to Week 96/144.
AUPH
Aurinia Pharmaceuticals Inc.
litigation
positive
materiality 0.70
August 19, 2026, 4:11 PM ET
Aurinia settles Teva patent litigation; generic voclosporin launch no earlier than Dec 7, 2036
- Settlement with Teva resolves generic patent litigation over Teva's ANDA for 7.9 mg voclosporin oral capsules.
- Teva stipulates U.S. Patent Nos. 10,286,036 and 11,622,991 valid, enforceable, and infringed; patents expire December 2037.
- Teva may launch generic voclosporin no earlier than Dec 7, 2036, subject to FDA approval and certain defined contingencies.
MREO
Mereo BioPharma Group plc
regulatory
negative
materiality 0.60
August 19, 2026, 7:52 AM ET
Mereo BioPharma gets second Nasdaq notice; extra 180 days to meet $1 bid price
- Received second Nasdaq notice on Aug 18, 2026; new compliance deadline Feb 16, 2027.
- Must close at $1.00+ for 10 consecutive business days to regain compliance.
- If not compliant by Feb 16, 2027, Nasdaq will issue delisting notice; company may appeal.
debt
negative
materiality 0.70
August 19, 2026, 8:30 AM ET
Arrive AI cuts workforce 20%, secures $100K note, lowers floor price to $0.10
- VWAP fell below $0.25 floor, triggering $962,500 mandatory monthly repayments under prior prepaid purchases.
- Entered Pre-Paid Purchase No. 5: Streeterville pays $100,000 for $108,000 note (8% interest, $8,000 OID).
- Floor price reduced from $0.25 to $0.10 per share for Pre-Paid Purchases No. 2, 3, and 5.
other material
negative
materiality 0.90
August 19, 2026, 5:05 PM ET
OSR Health faces Nasdaq delisting; trading suspended Aug 26, 2026; appeal planned
- Nasdaq Staff Determination dated Aug 19, 2026: delisting for failure to meet $1.00 minimum bid (Rule 5550(a)(2)).
- Trading in OSRH and OSRHW suspended at open on Aug 26, 2026; Form 25-NSE to be filed unless Panel stays.
- Company will request Nasdaq Hearings Panel hearing by 4:00 p.m. ET Aug 26, 2026; no stay of suspension.
HIVE
HIVE Digital Technologies Ltd.
other material
positive
materiality 0.80
August 19, 2026, 5:17 PM ET
BUZZ HPC signs $350M 5-year GPU cloud deal with investment-grade customer
- Five-year GPU cloud services agreement with investment-grade enterprise customer; $350M TCV, ~$70M annualized revenue.
- Deployment: 2,016 NVIDIA Blackwell Ultra GPUs in GB300 NVL72 systems at Bell AI Fabric, Merritt, BC; operational Q4 2026.
- Capex ~$185M; customer deposit ~10% ($35M) of TCV; HIVE retains ownership of AI infrastructure.